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Cannabidiol is a herbal compound that has been found to be effective in improvement of inflammatory demyelinating 
diseases and could be useful to increase supportive factors in remyelination. It is derived from Cannabis sativa known as 
Marijuana. The aim of this research was to investigate the changes in the expression of neuroprotective NTF-3 and IGF-1 
genes with focus on multiple sclerosis (MS) disease after treating U373-MG glial cells with cannabidiol. In this regard 
U373-MG astrocyte cells were treated at timescales of 24 h, 48 h, and 72 h with doses of cannabidiol, the total cellular RNA 
was extracted and converted into cDNA. Eventually, changes in NTF-3 and IGF-1 gene expressions were evaluated by 
quantitative real time polymerase chain reaction (qRT-PCR). 
The results supported the theory that very low doses of the drug are neuroprotective for glial cells and CNS. Probably 
cannabidiol fulfills it by stimulating the growth and differentiation of oligodendrocyte precursor cells to become mature 
oligodendrocytes. However, further research work and application of complementary techniques are necessary to ensure 
trust worthy in vivo and in vitro results. 
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MS is the prominent cause of disability in young 
adults (1-3). Although the cause of MS is still 
unknown and there is no certain treatment for it, it is 
believed that various changes in different genes and 
environmental factors play a role in causing this 
disease. Demyelination in Central Nervous System 
(CNS) is the main pathological characteristic of MS 
which is an initial inflammatory process; repetition of 
inflammation eventually leads to the loss of axons, 
chronic neurological disabilities and neuropathological 
defects (2,4,5). 
Remyelination– the production of new myelin in the 
adult CNS - is a primary repair mechanism that occurs in 
areas of neuronal injury. This improves neurological 
function and messaging and leads to creating myelin 
sheath which is often thinner and shorter than non-
remyelination axons; however, this process is restricted 
gradually and will be removed during disease progress 
(3,6). Generally, it is believed that remyelination occurs 
via Oligodendrocyte Precursors Cells (OPCs) that are 
distributed throughout the CNS (1, 3, 4, 6, 7). To this 
end, OPCs must be dispatched to the demyelinating 
areas and converted (after differentiation) into mature 
myelination cells which surround the axon membrane 
(1,3-6,8). Mature oligodendrocytes move toward axons, 
make contact with them and cover them in the form of 
concentric layers of myelin membrane. Ultimately, by 
compressing the layers around axons, the functional 
myelin be formed (3) it appears that astrocytes are 
involved in remyelination as in vivo and in vitro studies 
on the processes of demyelinating and remyelinating 
have demonstrated that activation, proliferation and 
migration of OPCs into the affected areas occurs by 
release of chemotropic and neuroprotective factors, as 
well as expression specific transcription factors such  
as NKX2 and Olig 2 that are secreted by activated 
microglia and or astrocytes (1,3,4). 
One of these neuroprotective factors is NTF-3 from 
a family of neurotrophic factors (NTFs) which is 
considered as a group of protein growth factors  
(9-11). The neurotrophin family is a family of mediators 
which are soluble in water and contain nerve growth 
factor (NGF), Brain-derived neurotrophic factor 
(BDNF), neurotrophin 3 (NT-3), and neurotrophin 4 
(NT-4) (10-12). It is proposed that pathogenesis of 
neurodegenerative disorders, may be the result of ————— *Corresponding author 
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changes in the expression of neurotrophic factors and 
their receptors (10). NT-3 is the third neurotrophic 
factor that was detected after NGF and BDNF factors 
in 1990. Studies using EAE and in vitro studies 
suggest that NT-3 increases myelination of neurons 
by inducing differentiation of OPCs into myelin-
forming cells (9). Another important neuroprotective 
factor is IGF that is a nutritional support factor of  
the oligodendrocyte cell lines, and includes IGF-1, 
IGF-2, and insulin-like growth factor-binding protein 
(IGF BPS) (6).  
Numerous studies have suggested that the Cannabis 
sativa plant can probably increase the level of the 
neuroprotective factors in the body and play an 
important role in the improvement of patients. It is 
believed that cannabinoids mainly act via two different 
receptors: (i) the cannabinoid-1 (CB-1) receptor, 
predominantly expressed on the neurons; and (ii) the 
cannabinoid-2 (CB-2) receptor, predominantly expressed 
on cells of the immune system (13). However, CB-2 
receptor expression is seen on glial as well as on 
neuronal cells in several areas of the brain (14).  
The aim of this study was to evaluate the therapeutic 
potential of cannabidiol (non-psychoactive compound of 
cannabis) in increasing neuroprotective factors, NTF-3 
and IGF-1. We hope that the pharmaceutical industry 
could utilize compounds that can increase levels of 
neuroprotective factors and play an important role to 
improve MS patients’ condition. 
 
Methodology 
 
Cell culture 
In the present study, U373-MG cell lines (purchased 
from National Cell Bank of Iran (NCBI) at Pasteur 
Institute) were used. U373-MG is a human glioblastoma 
astrocytoma that can be grown in adherent cultures. It 
was maintained while supplemented with 10% heat-
inactivated fetal bovine serum (FBS). Cells were kept at 
37°C, under a humidified atmosphere of 95% and 5% 
CO2 in 25 mL flasks. 
 
Dilution cannabidiol 
Cannabidiol (solution) was purchased from Sigma 
Aldrich Company. For each use, it was diluted to the 
amount desired with RPMI solution. 
 
Cytotoxicity assay (MTT) 
After determining the viability of the cells with 
Trypan blue dye, the researchers used MTT assay to 
assess toxicity of doses of cannabidiol. In this test, 
cells in 96-well plates at 6,000 cells with a final 
volume of 200 µL of 4% FBS at 24 h, 48 h and 72 h 
with different doses of drug (0 to 50 mM) were 
examined. Finally, the absorption of each well was 
read by analyzer device at a wavelength of 540 nm. 
 
Treatment 
Cells were seeded in a 6-well plate at a density  
of 3×105 and then treated with cannabidiol at a 
concentration of 0, 0.5, 1, and 2 µM cannabidiol.  
The plates were incubated in specified periods of time 
(24 h, 48 h and 72 h). 
 
RNA isolation, reverse transcription (RT), and 
real-time PCR 
Total RNA was extracted from astrocytes using 
RNA isolation reagent (TRIzol reagent, Invitrogen). 
The researchers conducted reverse transcription 
polymerase chain reaction for the conversion of RNA 
into cDNA, using RNA-dependent DNA polymerase 
enzyme (Thermo Scientific, USA). Based on the 
concentration obtained by Picodrop of RNA samples, 
equal amounts of RNA from each treated sample were 
used for cDNA synthesis. The primers were 
purchased from GENERAY Company. Real-time 
PCR was performed in the Rotor-Gene Q (Qiagen, 
Germany) and SYBR Green Universal PCR Master 
Mix (Amplicon), DNA template (cDNA), water and 
forward and reverse primers were used in this 
reaction. The GAPDH gene was selected as an 
internal control. The PCR protocol for NTF-3 gene 
consisted of 40 cycles of denaturation at 95°C for 25 s 
followed by 60°C for 25 s annealing and 72°C for  
35 s to allow extension and amplification of the target 
sequence. The annealing for IGF-1 gene was 57°C for 
25 s. primer sequences are shown in table (Table 1). 
 
Statistical Analysis 
All experiments, including MTT and qRT-PCR 
assays were performed in triplicate and the data were 
statistically analyzed by SPSS PASW statistic 18 and 
were evaluated by using linear and bivariate 
regression correlation tests. Linear and bivariate 
regression correlation tests were used for MTT and 
qRT-PCR-related data analysis, such as relationship 
Table 1 — Primer sequences 
NTF-3 primers 
 
5'-TGCTCTTAACACCTGTGTTTCCT -3' F 
5'-TTGAGCGAGTCTTCTGGCAA-3' R  
IGF-1 primers 5'-GTGACATTGCTCTCAACATCTCC-3' F 
5'-TGGGTTGGAAGACTGCTGATT-3' R 
GAPDH primers 5'-TTCAACAGCGACACCCACTC-3' F 
5'-GGTCTCTCTCTTCCTCTTGTGC-3' R 
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between IGF-1 gene expression and different doses of 
cannabidiol. 
 
Results 
 
Results of MTT assay 
Two sets of time periods (48 h and 72 h) were 
compared to a 24 h period indicating the effect of time 
on cytotoxicity of the cannabidiol on the cells. Column 
chart and linear graph of the IC50 and percentage of cell 
viability U373-MG with cannabidiol are shown in Fig. 1 
and Fig. 2. 
 
Results of Real Time PCR reaction 
NTF3 and IGF-1 gene expression changes, as a 
result of different doses of cannabidiol, are shown in 
Fig. 3 & Fig. 4. 
 
Discussion 
Recent studies on animal models and human 
populations using drugs based on cannabinoids 
derived from cannabis, offer promising results for the 
treatment of various disorders and diseases such as 
cancer, neurodegenerative, and chronic inflammatory 
diseases (15). At least 60 active compounds can be 
extracted from this plant, all of which are known as 
cannabinoids and among them cannabidiol has 
received considerable attention in medicine, recently. 
This is due to its antioxidant and neuroprotective 
activity and ability to regulate the immune system  
as well as its lack of psychoactive effects (3,16-18). 
Most previous studies have suggested that 
cannabinoids are modulators of immune responses 
and have anti-inflammatory roles which are carried 
out by TH1 response switch to TH2 responses. Thus, 
by reducing inflammation and secretion of anti-
inflammatory cytokines, the disease process can be 
slowed down (19,20). 
In the mid-1980s, studies conducted on mice cells 
treated with THC (the main composition of the cannabis 
plant), showed reduced levels of IFN-1 (IFN-β and 
IFNα) after stimulation with LPS. the first evidence 
provided basis for the fact that cannabinoids can regulate 
the production of cytokines (21). Most of the later 
experiments focused on changes in inflammatory factors 
after the administration of cannabinoid in vitro and in 
vivo; these experiments were developed to studies 
investigating other factors including neuroprotective 
factors. One of the studies dealing with in vivo 
  
Fig. 1 — IC50 value of CBD (µM) in periods of 24 h, 48 h and
72 h on cell line U373-MG with Pv≤0.01. Two sets of time
periods (48 h and 72 h) were compared to a 24 h period indicating
the effect of time on cytotoxicity of the cannabidiol on the cells. 
 
  
Fig. 2 — Linear graph of the percentage of cell viability U373-
MG with cannabidiol in periods of 24 h, 48 h and 72 h (Pv≤0.01). 
  
Fig. 3 — Chart of NTF3 gene expression changes as a result of
different doses of cannabidiol Compared with the control over
periods of 24 h, 48 h and 72 h (Pv≤0.01) 
 
  
Fig. 4 — Chart of IGF-1 gene expression changes as a result of
different doses of cannabidiol compared with the control over a
period of time (24 h, (Pv≤0.05); 48 h and 72 h (Pv≤0.01)). 
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treatments with CBD, found an increase in brain-derived 
neurotrophic factor, also known as BDNF in peripheral 
blood cells of mice (22).  
The most abundant type of glial cells is astrocyte that 
has Cannabinoid receptors. The functional role of 
astrocytes in the pathogenesis of neurodegenerative and 
neuroinflammatory diseases has been demonstrated in 
the CNS (23). Binding of cannabidiol ligand to CB1 and 
CB2 receptors causes the activation of routes that lead to 
the regulation of immune responses, inflammation, and 
secretion of neuroprotective factors (21,24). NTF3 is a 
member of the neurotrophin family of growth factors.  
In this study, it was shown that low concentrations  
of cannabidiol can enhance its secretion. Increased 
secretion of this factor from astrocytes affects the 
oligodendrocyte cells and stimulates the growth and 
differentiation of oligodendrocyte progenitor cells to 
form mature oligodendrocytes. 
IGFs are neuroprotective trophic factors for cells of 
the oligodendrocyte lineage which are expressed at high 
levels in neuron-rich areas of the brain (6). Previous 
studies based on the injection of IGF-1 into animals with 
EAE, have reported a decrease in the numbers and area 
of demyelinated lesions and an increase in the number of 
axons containing regenerating myelin segments as well 
as an enhancement in myelin gene expression. These 
changes have been shown to be associated with rapid 
clinical and pathological recovery in the treated animals 
(6,25). This factor is effective in improving multiple 
sclerosis patients’ condition, possibly through increased 
expression of transcription factors. These factors are 
involved in stimulating the growth and differentiation  
of oligodendrocyte precursor cells into mature 
olygodendrocytes that make myelin, and are playing a 
neuroprotective role in increasing remyelination in 
nervous system. 
In this study, 0.5 µM of cannabidiol had the 
greatest effect on the expression of NTF-3 and IGF-1 
genes in 72 h (Pv≤0.01). This indicated the influence 
of time factor on the effect of this drug. However, the 
best effectiveness in 24 and 48 h treatments with 
cannabidiol was observed at a dose of 1 µM (Pv≤0.01 
and Pv≤0.05 respectively).  
Moreover, 2 µM of cannabidiol, approximately in 
all of 3 treatment periods, resulted in a decreasing 
trend in the expression of mentioned genes. This  
trend was significant for NTF-3 only at 72 h period 
(Pv≤0.01). This decreasing trend in the last treatment 
period can be due to the stimulation of apoptosis 
factors which consequently leads to morphology 
change and ultimately cell death. 
Conclusion 
Scientific research on the effects of cannabinoids and 
especially one of them that called cannabidiol (non-
psychoactive combination) continues to develop and to 
find the therapeutic potential and neuroprotective 
properties of such compounds for the treatment of 
neurodegenerative and neuroinflammatory diseases  
such as multiple sclerosis. In this study, data showed 
significantly (Pv≤0.05) increased expression of NTF3 
and IGF-1 genes after treatment of U373-MG cells with 
cannabidiol. Doses of 0.5 and 1 µM of this drug offered 
results supporting its neuroprotective effects; however, 
further studies with complementary techniques are 
necessary to ensure obtaining of trustworthy in vivo and 
in vitro results. 
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